Project Grant R01AI196126
- Federal Grant Award Summary Mayo Clinic received a $624,521 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on February 24, 2026, with a completion date of January 31, 2031. The award supports research investigating the regulation of target cell survival by TBK1 (TANK-Binding Kinase 1) and IKKε (Inducible IκB Kinase Epsilon) kinases in the context of immune-mediated tumor cell...
- Federal Grant Award Summary Mayo Clinic received a $441,098 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with a completion date of June 30, 2027. The research project, conducted at Mayo Clinic's Minnesota facility, investigates the antagonistic actions of IRF4 (Interferon Regulatory Factor 4) and BACH2 (BTB Domain and CNC Homolog 2) transcription...
- Federal Project Grant Award Summary Mayo Clinic Arizona, a nonprofit academic medical center and research institution, received a $486,109 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective July 1, 2025, through June 30, 2027, supports investigator-initiated biomedical research examining Type 2 immune responses in endotoxemia-induced lung injury. The research project...
- Federal Project Grant Award Summary Mayo Clinic received a $443,850 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 4, 2026, with a completion date of January 31, 2028. The research initiative, conducted at Mayo Clinic's Rochester, Minnesota facility, investigates how intestinal exposure to Candida albicans during early life influences the developing immune...
- Federal Grant Award Summary Mayo Clinic received a $689,081 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026, through March 31, 2031. The award supports biomedical research to establish the etiology of chronic placental villitis of unknown etiology (VUE), an inflammatory placental condition characterized by maternal CD8+ T cell infiltration into chorionic villi...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University a Project Grant of $332,690 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2026. This award supports investigator-initiated biomedical research examining the mechanisms by which antinuclear antibodies (ANA) influence alloimmune...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $657,673 to the Regents of the University of Minnesota under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 22, 2025, for a five-year research project concluding June 30, 2030. This Project Grant funds research investigating non-deletional CD8+ T cell tolerance mechanisms, which are critical to understanding how the immune system prevents autoimmune disease....
- Federal Project Grant Award Summary Mayo Clinic received a $754,546 Project Grant awarded September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The award supports research to develop automated data abstraction methods leveraging large language models to improve medical registry curation in orthopedic joint replacement procedures. The project addresses a...
- Federal Project Grant Award Summary Mayo Clinic received a $441,100 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. The award supports research focused on developing in vivo Ebola virus (EBOV) life cycle modeling systems under biosafety level-2 (BSL-2) conditions. The research objectives include generating two murine models to...
- Federal Grant Award Summary Mayo Clinic received a $250,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 5, 2025, with a completion date of August 31, 2027. The award supports a two-year research initiative investigating the role of TFEB (Transcription Factor EB) transcription factor in age-associated B cells (ABCs) and autoimmunity, with particular focus on systemic lupus...
Project Grant Award Summary Mayo Clinic received an $800,097 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award supports a research initiative titled "Transforming ANA Testing: Leveraging Epidemiology and AI to Detect Autoimmune Disease," conducted at Mayo Clinic's Rochester, Minnesota facility. The project addresses critical clinical challenges in antinuclear antibody (ANA) testing by combining epidemiological data analysis, biobank resources, and artificial intelligence technologies to improve diagnostic accuracy and standardization of ANA indirect immunofluorescence assays used in detecting autoimmune diseases such as systemic lupus erythematosus. The research deliverables include two primary aims: establishing the long-term risk trajectory of developing autoimmune diseases in ANA-positive individuals and enhancing the standardization and predictive integration of ANA immunofluorescence testing through AI-enabled analysis. The project will leverage existing epidemiological datasets and biobank resources to address diagnostic ambiguity, reduce variability introduced by manual visual interpretation of test results, and ultimately improve clinical outcomes by reducing unnecessary referrals, over-treatment, and patient anxiety while supporting healthcare systems facing rheumatology specialist shortages.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $800.1k | 3/27/26 |